VIS705 for Pseudomonas Aeruginosa
VIS705 is an antibody-drug conjugate, or ADC, for the treatment of Pseudomonas aeruginosa, a type of Gram-negative bacterial infection. We are developing VIS705 as a single-dose curative therapy, engineered to kill all strains of the deadly Pseudomonas bacteria, including strains that have been found to be multi-drug resistant. VIS705 is a single molecule that combines a disease-targeting monoclonal antibody with a potent, anti-microbial cell-killing peptide. This construct provides an efficient and robust two-step mechanism to target and kill the bacteria: first, the antibody component of VIS705 targets and binds to the Pseudomonas bacteria and directs the body’s immune system to attack the bacteria, and secondly, VIS705 delivers a potent anti-microbial peptide that rapidly kills the targeted bacteria.

We have been awarded a contract from Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), the world’s largest public-private partnership devoted to antibacterial preclinical research and development, that includes committed funding of $3.0 million for VIS705, with the option, based on successful progression through milestones established by CARB-X, to increase the total funding up to $7.2 million. This CARB-X award will enable us to accelerate our research and preclinical development of VIS705, leading to the expected submission of an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) and the subsequent initiation of first-in-human clinical trials.

About Pseudomonas Aeruginosa
Gram-negative bacteria, which are the cause of many healthcare-associated infections including pneumonia, bloodstream infections, urinary tract infections, and surgical site infections, have become increasingly resistant to many available antibiotic treatments. These infections have been associated with increased patient mortality and significant healthcare costs. Pseudomonas is one of the primary causes of infection by multi-drug resistant Gram-negative bacteria and can be deadly for immunocompromised patients. According to the United States Centers for Disease Control (CDC), an estimated 51,000 Pseudomonas infections occur in the United States each year. More than 6,000 of these are multidrug-resistant, with roughly 400 deaths per year attributed to such infections. Over the past two decades, the percentage of Pseudomonas strains resistant to multiple antibiotics has doubled in ICU patients, with the most significant increase in patients suffering from pneumonia. The CDC has included multidrug-resistant Pseudomonas on its “Serious Threats” list, meaning that this bacteria poses a significant concern and requires prompt and sustained action to ensure the problem does not escalate. In addition, the World Health Organization recently declared carbapenem-resistant Pseudomonas as a Priority 1 Critical pathogen on its “Priority Pathogen” list.

As of 09/15/17

Visterra, Inc.  |  275 2nd Avenue  |  Waltham, MA 02451  |  617-498-1070  |  © 2018 Visterra, Inc. All Rights Reserved.